Madrigal Pharmaceuticals Announces $300+ Million In Financing Events To Advance Resmetirom Program
Amount Raised
$300 Million
Round Type
Funding Round
ConshohockenBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit Facility.
Who to call at Madrigal Pharmaceuticals, and when
A new round usually means Madrigal Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Madrigal Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Madrigal Pharmaceuticals, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Madrigal Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Madrigal Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.